Memo Therapeutics AG Appoints Seasoned Executives Elias Papatheodorou as Chairman and Dr. Thomas Taapken as Member to Board of Directors

Schlieren, Switzerland – July 6, 2020 – Memo Therapeutics AG (“Memo”), an innovator in the field of antibody discovery and development, announced today the appointment of Elias Papatheodorou as Chairman of the Board of Directors. He is joined by Dr. Thomas Taapken, who has been elected as a Member of the Board of Directors.

Mr. Papatheodorou has over 20 years of C-level experience in all aspects of pharmaceutical commercialization, including sales & marketing, business development, M&A, and operations. He has a proven track-record of managing clinical-stage organizations and preparing them for sale. He is currently the CEO of Genkyotex, which was sold to Calliditas Therapeutics, and was previously the CBO at Covagen, which was acquired by Janssen Pharmaceuticals.

Dr. Thomas Taapken has over 20 years of experience in the life science industry at the executive management level. His experience spans public & private financings, IPO, corporate & business development, and research. He is currently the CFO of InflaRx and has previously held various C-level positions at both private and publicly listed companies, including Medigene, Epigenomics and Biotie Therapies. He holds a PhD in Organic Chemistry from Technical University of Berlin.

“We are thrilled to welcome Elias and Thomas to Memo Therapeutics AG’ Board of Directors,” said Dr. Karsten Fischer, CEO. “Elias and Thomas bring a wealth of financial, operational and industry experience to our team and will be instrumental in supporting our upcoming transition to a clinical-stage organization and positioning the company for future strategic transactions.”

About Memo Therapeutics AG
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. The company’s antibody discovery platform uses robust, simple and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency and sensitivity.

The platform captures and preserves entire B-cell repertoires from any donor species and any B-cell type in recombinant form for display using mammalian cells. The antibody repertoires are subsequently screened in single-cell format using microfluidic screening technology that can assess millions of candidate antibodies directly in functional assays, resulting in recombinant clonal cell lines expressing monoclonal antibodies (mAbs) with the desired functional properties.

Exploiting the power of its microfluidic single-cell molecular cloning and screening technologies, Memo Therapeutics AG engages in antibody discovery across species and indications for proprietary and partnered projects. The company’s current pipeline features programs in infectious diseases and immuno-oncology. Memo Therapeutics AG is a private company located in Bio-Technopark Zurich, Switzerland.